摘要
You have accessJournal of UrologyKidney Cancer: Basic Research I1 Apr 2015MP39-20 MOLECULAR MECHANISM UNDERLYING CYTOTOXIC ACTIVITY OF AXITINIB IN SUNITINIB-RESISTANT HUMAN RENAL CELL CARCINOMA ACHN CELLS Akira Miyazaki, Hideaki Miyake, and Masato Fujisawa Akira MiyazakiAkira Miyazaki More articles by this author , Hideaki MiyakeHideaki Miyake More articles by this author , and Masato FujisawaMasato Fujisawa More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.770AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Although axitinib and sunitinib are shown to exert antitumor activity against renal cell carcinoma (RCC) based on common mechanism characterized by the inhibition of tumor cell proliferation as well as angiogenesis through the inactivation of receptor tyrosine kinases, axitinib has been demonstrated to have a powerful therapeutic activity in patients with RCC showing acquired resistance to sunitinib. The objective of this study was to clarify molecular mechanism involved in the cytotoxic activity of axitinib in sunitinib-resistant human RCC cells. METHODS A parental human RCC cell line, ACHN (ACHN/P), was continuously exposed to increasing doses of sunitinib, and a cell line resistant to sunitinib (ACHN/R), showing an approximately 5-fold higher IC50 than that of ACHN/P, was developed. Differences in molecular phenotypes following treatment with sunitinib or axitinib between these two cell lines were compared. RESULTS ACHN/R appeared to acquire significant cross resistance to another potential tyrosine kinase inhibitor, sorafenib; however, there were no significant differences in the sensitivities to axitinib in addition to the Mammalian target of rapamycin inhibitors, temsirolimus and everolimus, between ACHN/P and ACHN/R. In ACHN/P, both sunitinib and axitinib markedly inhibited the expression levels of phosphorylated Akt, p44/42 mitogen activated protein kinase (MAPK) and vascular endothelial growth factor receptor-2 (VEGFR-2). In ACHN/R, however, phosphorylation of Akt, p44/42 MAPK and VEGFR-2 were maintained following treatment with sunitinib, whereas treatment with axitinib resulted in the marked down-regulation of both phosphorylated p44/42 MAPK and VEGFR-2, but not that of Akt. Furthermore, additional treatment with LY294002, a specific inhibitor of AKT, significantly increased the sensitivity of ACHN/R to axitinib, but not that of ACHN/P. In vivo growth of ACHN/R in nude mice after treatment with axitinib was also significantly suppressed compared with that following treatment with sunitinib, accompanying the marked inhibition of phosphorylated p44/42 MAPK and VEGFR-2. CONCLUSIONS Antitumor activity of axitinib in RCC cells even after the acquisition of resistance to sunitinib could be explained, at least in part, by the inactivation of p44/42 MAPK and VEGFR-2, which were persistently phosphorylated following treatment with sunitinib, and that combined treatment with a specific inhibitor of Akt may further enhance the cytotoxic activity of axitinib in sunitinib-resistant human RCC cells. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e462 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Akira Miyazaki More articles by this author Hideaki Miyake More articles by this author Masato Fujisawa More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...